Low-level lead exposure and the prevalence of gout: An observational study

Annals of Internal Medicine

Volumn 157, Issue 4, 2012, Pages 233-241

  Krishnan, Eswar ^a   Lingala, Bharathi ^a   Bhalla, Vivek ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DIURETIC AGENT; LEAD; PURINE; URATE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; EXPOSURE; FEMALE; GOUT; HEALTH SURVEY; HUMAN; HYPERTENSION; HYPERURICEMIA; INCOME; KIDNEY FUNCTION; LEAD BLOOD LEVEL; LEAD POISONING; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RACE; RISK ASSESSMENT; URIC ACID BLOOD LEVEL;

EID: 84865650915     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-157-4-201208210-00003     Document Type: Article

References (58)

1. Poór G, Mituszova M. Saturnine gout. Baillieres Clin Rheumatol. 1989;3:51-61.
2. Hernberg S. Lead poisoning in a historical perspective. Am J Ind Med. 2000; 38:244-54.
3. Thottam J. More trouble in toyland. Amid new recalls of Chinese goods, U.S. toymakers are scrambling to make the holidays safer. Time. 2007;170:50-1.
4. Perazella MA. Lead and the kidney: nephropathy, hypertension, and gout. Conn Med. 1996;60:521-6.
5. Muntner P, Menke A, DeSalvo KB, Rabito FA, Batuman V. Continued decline in blood lead levels among adults in the United States: the National Health and Nutrition Examination Surveys. Arch Intern Med. 2005;165:2155-61.
6. Centers for Disease Control and Prevention (CDC). Adult blood lead epidemiology and surveillance-United States, 2005-2007. MMWR Morb Mortal Wkly Rep. 2009;58:365-9.
7. Wigle DT, Lanphear BP. Human health risks from low-level environmental exposures: no apparent safety thresholds. PLoS Med. 2005;2:e350.
8. Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation. 2006;114:1388-94.
9. Kim R, Rotnitsky A, Sparrow D, Weiss S, Wager C, Hu H. A longitudinal study of low-level lead exposure and impairment of renal function. The Normative Aging Study. JAMA. 1996;275:1177-81.
10. Emmerson BT. The clinical differentiation of lead gout from primary gout. Arthritis Rheum. 1968;11:623-34.
11. Ludwig GD. Saturnine gout; a secondary type of gout. AMA Arch Intern Med. 1957;100:802-12.
12. Morgan JM, Burch HB. Comparative tests for diagnosis of lead poisoning. Arch Intern Med. 1972;130:335-40.
13. Campbell BC, Moore MR, Goldberg A, Hernandez LA, Dick WC. Subclinical lead exposure: a possible cause of gout. Br Med J. 1978;2:1403.
14. Shadick NA, Kim R, Weiss S, Liang MH, Sparrow D, Hu H. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. J Rheumatol. 2000;27:1708-12.
15. Lin JL, Tan DT, Ho HH, Yu CC. Environmental lead exposure and urate excretion in the general population. Am J Med. 2002;113:563-8.
16. Baker MD, Johnston JR, Maclatchy AE, Bezuidenhout BN. The relationship of serum uric acid to subclinical blood lead. Rheumatol Rehabil. 1981;20: 208-10.
17. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Web site. Accessed at www.cdc.gov/nchs/nhanes.htm on 27 June 2012.
18. Loghman-Adham M. Renal effects of environmental and occupational lead exposure. Environ Health Perspect. 1997;105:928-38.
19. Centers for Disease Control and Prevention. Laboratory Procedure Manual: Lead Cadmium Mercury. Atlanta, GA: Centers for Disease Control and Prevention; 2004. Accessed at www.cdc.gov/nchs/data/nhanes/nhanes_07_08/PbCd_E_met_lead_cadmium.pdf on 27 June 2012.
20. Centers for Disease Control and Prevention. Laboratory Procedure Manual: Uric Acid. Atlanta, GA: Centers for Disease Control and Prevention; 2004. Accessed at www.cdc.gov/nchs/data/nhanes/nhanes_03_04/l40_c_met_uric_acid.pdf on 27 June 2012.
21. Selvin E, Manzi J, Stevens LA, Van Lente F, Lacher DA, Levey AS, et al. Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. Am J Kidney Dis. 2007;50: 918-26.
22. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-54.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
24. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32 Suppl 1:S62-7.
25. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72.
26. Souci SW, Fachmann W, Kraut H, Scherz H, Senser F. Food Composition and Nutrition Tables. 6th rev. and comp. ed. Stuttgart, Germany: Medpharm; 2000.
27. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093-103.
28. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895-900.
29. Gelber AC, Klag MJ, Mead LA, Thomas J, Thomas DJ, Pearson TA, et al. Gout and risk for subsequent coronary heart disease. The Meharry-Hopkins Study. Arch Intern Med. 1997;157:1436-40.
30. McAdams MA, Maynard JW, Baer AN, Köttgen A, Clipp S, Coresh J, et al. Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol. 2011;38:135-41.
31. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54:2688-96.
32. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363:1277-81.
33. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894-900.
34. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008;47:1567-70.
35. Barbosa F Jr, Tanus-Santos JE, Gerlach RF, Parsons PJ. A critical review of biomarkers used for monitoring human exposure to lead: advantages, limitations, and future needs. Environ Health Perspect. 2005;113:1669-74.
36. Emmerson BT. Chronic lead nephropathy: the diagnostic use of calcium EDTA and the association with gout. Australas Ann Med. 1963;12:310-24.
37. Klinenberg JR. Saturnine gout-a moonshine malady. N Engl J Med. 1969; 280:1238-9.
38. Morgan BW, Todd KH, Moore B. Elevated blood lead levels in urban moonshine drinkers. Ann Emerg Med. 2001;37:51-4.
39. Batuman V, Maesaka JK, Haddad B, Tepper E, Landy E, Wedeen RP. The role of lead in gout nephropathy. N Engl J Med. 1981;304:520-3.
40. Rothman KJ, Greenland S. The emergence of modern epidemiology. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. Philadelphia: Lippincott Williams & Wilkins; 1998:4.
41. de Klerk NH, English DR, Armstrong BK. A review of the effects of random measurement error on relative risk estimates in epidemiological studies. Int J Epidemiol. 1989;18:705-12.
42. Coresh J, Stevens LA. Kidney function estimating equations: where do we stand? Curr Opin Nephrol Hypertens. 2006;15:276-84.
43. Madero M, Sarnak MJ, Stevens LA. Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertens. 2006;15:610-6.
44. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006;354: 2473-83.
45. Wengrovitz AM, Brown MJ; Advisory Committee on Childhood Lead Poisoning, Division of Environmental and Emergency Health Services, National Center for Environmental Health. Recommendations for blood lead screening of Medicaid-eligible children aged 1-5 years: an updated approach to targeting a group at high risk. MMWR Recomm Rep. 2009;58(RR-9):1-11.
46. Barry PS, Mossman DB. Lead concentrations in human tissues. Br J Ind Med. 1970;27:339-51.
47. Wedeen RP. Bone lead, hypertension, and lead nephropathy. Environ Health Perspect. 1988;78:57-60.
48. Batuman V. Lead nephropathy, gout, and hypertension. Am J Med Sci. 1993;305:241-7.
49. Koster J, Erhardt A, Stoeppler M, Mohl C, Ritz E. Mobilizable lead in patients with chronic renal failure. Eur J Clin Invest. 1989;19:228-33.
50. Gulson BL, Mizon KJ, Korsch MJ, Howarth D, Phillips A, Hall J. Impact on blood lead in children and adults following relocation from their source of exposure and contribution of skeletal tissue to blood lead. Bull Environ Contam Toxicol. 1996;56:543-50.
51. Gulson BL, Mahaffey KR, Mizon KJ, Korsch MJ, Cameron MA, Vimpani G. Contribution of tissue lead to blood lead in adult female subjects based on stable lead isotope methods. J Lab Clin Med. 1995;125:703-12.
52. Smith DR, Osterloh JD, Flegal AR. Use of endogenous, stable lead isotopes to determine release of lead from the skeleton. Environ Health Perspect. 1996; 104:60-6.
53. Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epide- miologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect. 1998;106:1-8.
54. U.S. Environmental Protection Agency. Review of Studies Addressing Lead Abatement Effectiveness. Washington, DC: U.S. Environmental Protection Agency; 1995.
55. Roberts JR, Reigart JR, Ebeling M, Hulsey TC. Time required for blood lead levels to decline in nonchelated children. J Toxicol Clin Toxicol. 2001;39: 153-60.
56. Schock MR, Hyland RN, Welch MM. Occurrence of contaminant accumulation in lead pipe scales from domestic drinking-water distribution systems. Environ Sci Technol. 2008;42:4285-91.
57. Kosnett MJ. Chelation for heavy metals (arsenic, lead, and mercury): protective or perilous? Clin Pharmacol Ther. 2010;88:412-5.
58. Miranda ME, Puig JG, Mateos FA, Ramos TH, Herrero E, González A, et al. The role of lead in gout nephropathy reviewed: pathogenic or associated factor? Adv Exp Med Biol. 1991;309A:209-12.